Which has better earnings and valuation, GDRX or NRC?

GoodRx has higher revenue and earnings than National Research. GoodRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.48 $30.44M $0.04 86.25 National Research $137.39M 3.67 $11.60M $0.25 88.76

National Research (NRC) Competitors

$22.19 +0.37 (+1.70%)

As of 08/21/2026 04:00 PM Eastern

Compare

NRC vs. SDGR, TDOC, GDRX, CERT, and HSTM

Should you buy National Research stock or one of its competitors? National Research's main competitors and comparable companies include Schrodinger (SDGR), Teladoc Health (TDOC), GoodRx (GDRX), Certara (CERT), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does National Research compare to Schrodinger?

National Research (NASDAQ:NRC) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

47.3% of National Research shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

National Research has a net margin of 4.18% compared to Schrodinger's net margin of -20.98%. National Research's return on equity of 164.26% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Schrodinger	-20.98%	-16.37%	-8.19%

National Research currently has a consensus price target of $26.00, indicating a potential upside of 17.17%. Schrodinger has a consensus price target of $20.50, indicating a potential upside of 4.01%. Given National Research's stronger consensus rating and higher possible upside, analysts clearly believe National Research is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

National Research has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Schrodinger had 3 more articles in the media than National Research. MarketBeat recorded 3 mentions for Schrodinger and 0 mentions for National Research. Schrodinger's average media sentiment score of 1.03 beat National Research's score of -1.14 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Overall Sentiment
National Research	Negative
Schrodinger	Positive

National Research has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.67	$11.60M	$0.25	88.76
Schrodinger	$255.87M	5.69	-$103.26M	-$0.74	N/A

Summary

National Research and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks.

How does National Research compare to Teladoc Health?

National Research (NASDAQ:NRC) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

47.3% of National Research shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 9.2% of National Research shares are held by insiders. Comparatively, 0.7% of Teladoc Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Teladoc Health had 17 more articles in the media than National Research. MarketBeat recorded 17 mentions for Teladoc Health and 0 mentions for National Research. Teladoc Health's average media sentiment score of 0.61 beat National Research's score of -1.14 indicating that Teladoc Health is being referred to more favorably in the news media.

Company	Overall Sentiment
National Research	Negative
Teladoc Health	Positive

National Research has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.67	$11.60M	$0.25	88.76
Teladoc Health	$2.53B	0.46	-$200.32M	-$0.99	N/A

National Research presently has a consensus target price of $26.00, suggesting a potential upside of 17.17%. Teladoc Health has a consensus target price of $7.54, suggesting a potential upside of 17.56%. Given Teladoc Health's higher possible upside, analysts clearly believe Teladoc Health is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

National Research has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

National Research has a net margin of 4.18% compared to Teladoc Health's net margin of -7.13%. National Research's return on equity of 164.26% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Teladoc Health	-7.13%	-12.15%	-5.83%

Summary

National Research beats Teladoc Health on 9 of the 16 factors compared between the two stocks.

How does National Research compare to GoodRx?

GoodRx (NASDAQ:GDRX) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

GoodRx currently has a consensus price target of $4.23, suggesting a potential upside of 22.53%. National Research has a consensus price target of $26.00, suggesting a potential upside of 17.17%. Given GoodRx's higher probable upside, research analysts plainly believe GoodRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

National Research has a net margin of 4.18% compared to GoodRx's net margin of 2.07%. National Research's return on equity of 164.26% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
National Research	4.18%	164.26%	14.67%

GoodRx has higher revenue and earnings than National Research. GoodRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.48	$30.44M	$0.04	86.25
National Research	$137.39M	3.67	$11.60M	$0.25	88.76

GoodRx has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, National Research has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

In the previous week, GoodRx had 8 more articles in the media than National Research. MarketBeat recorded 8 mentions for GoodRx and 0 mentions for National Research. GoodRx's average media sentiment score of 0.37 beat National Research's score of -1.14 indicating that GoodRx is being referred to more favorably in the media.

Company	Overall Sentiment
GoodRx	Neutral
National Research	Negative

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 5.9% of GoodRx shares are owned by insiders. Comparatively, 9.2% of National Research shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GoodRx and National Research tied by winning 8 of the 16 factors compared between the two stocks.

How does National Research compare to Certara?

National Research (NASDAQ:NRC) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

National Research currently has a consensus price target of $26.00, suggesting a potential upside of 17.17%. Certara has a consensus price target of $8.28, suggesting a potential downside of 1.81%. Given National Research's stronger consensus rating and higher probable upside, equities research analysts plainly believe National Research is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

National Research has a net margin of 4.18% compared to Certara's net margin of -16.75%. National Research's return on equity of 164.26% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Certara	-16.75%	3.86%	2.65%

National Research has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Certara has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

In the previous week, Certara had 3 more articles in the media than National Research. MarketBeat recorded 3 mentions for Certara and 0 mentions for National Research. Certara's average media sentiment score of 1.55 beat National Research's score of -1.14 indicating that Certara is being referred to more favorably in the news media.

Company	Overall Sentiment
National Research	Negative
Certara	Very Positive

47.3% of National Research shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 9.2% of National Research shares are held by insiders. Comparatively, 1.1% of Certara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

National Research has higher earnings, but lower revenue than Certara. Certara is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.67	$11.60M	$0.25	88.76
Certara	$418.84M	3.07	-$1.60M	-$0.45	N/A

Summary

National Research beats Certara on 10 of the 17 factors compared between the two stocks.

How does National Research compare to HealthStream?

HealthStream (NASDAQ:HSTM) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

HealthStream currently has a consensus target price of $27.00, indicating a potential downside of 6.48%. National Research has a consensus target price of $26.00, indicating a potential upside of 17.17%. Given National Research's stronger consensus rating and higher probable upside, analysts clearly believe National Research is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

HealthStream pays an annual dividend of $0.14 per share and has a dividend yield of 0.5%. National Research pays an annual dividend of $0.64 per share and has a dividend yield of 2.9%. HealthStream pays out 19.4% of its earnings in the form of a dividend. National Research pays out 256.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. HealthStream has raised its dividend for 2 consecutive years.

HealthStream has higher revenue and earnings than National Research. HealthStream is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.77	$18.34M	$0.72	40.10
National Research	$137.39M	3.67	$11.60M	$0.25	88.76

HealthStream has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, National Research has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

HealthStream has a net margin of 6.60% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat HealthStream's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.60%	6.81%	4.64%
National Research	4.18%	164.26%	14.67%

In the previous week, HealthStream had 3 more articles in the media than National Research. MarketBeat recorded 3 mentions for HealthStream and 0 mentions for National Research. HealthStream's average media sentiment score of 0.63 beat National Research's score of -1.14 indicating that HealthStream is being referred to more favorably in the media.

Company	Overall Sentiment
HealthStream	Positive
National Research	Negative

69.6% of HealthStream shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 20.4% of HealthStream shares are held by insiders. Comparatively, 9.2% of National Research shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

HealthStream beats National Research on 11 of the 19 factors compared between the two stocks.

Get National Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRC vs. The Competition

Export

Metric	National Research	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$504.73M	$1.72B	$7.37B	$12.85B
Dividend Yield	2.88%	4.69%	2.53%	11.08%
P/E Ratio	88.76	21.09	272.60	24.24
Price / Sales	3.67	75.95	618.96	99.81
Price / Cash	17.65	31.69	78.62	53.99
Price / Book	76.52	6.98	13.05	6.20
Net Income	$11.60M	-$18.66M	$3.47B	$348.59M
7 Day Performance	4.72%	0.54%	2.09%	0.08%
1 Month Performance	6.53%	12.80%	6.64%	3.88%
1 Year Performance	44.37%	-17.12%	25.02%	16.98%

National Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRC National Research	2.0554 of 5 stars	$22.19 +1.7%	$26.00 +17.2%	+44.4%	$504.73M	$137.39M	88.76	490	Negative News Analyst Upgrade High Trading Volume
SDGR Schrodinger	1.0529 of 5 stars	$18.65 -0.6%	$20.25 +8.6%	-3.0%	$1.39B	$255.87M	N/A	790
TDOC Teladoc Health	3.4269 of 5 stars	$6.80 -3.9%	$7.54 +10.8%	-16.5%	$1.29B	$2.53B	N/A	5,600	Trending News Analyst Forecast Analyst Revision
GDRX GoodRx	4.3391 of 5 stars	$3.80 +3.8%	$4.16 +9.4%	-24.3%	$1.25B	$796.85M	95.02	950	News Coverage Analyst Forecast Insider Trade
CERT Certara	1.6079 of 5 stars	$8.13 +0.7%	$8.28 +1.8%	-26.5%	$1.23B	$418.84M	N/A	1,576	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRC) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

National Research (NRC) Competitors

NRC vs. SDGR, TDOC, GDRX, CERT, and HSTM

How does National Research compare to Schrodinger?

Summary

How does National Research compare to Teladoc Health?

Summary

How does National Research compare to GoodRx?

Summary

How does National Research compare to Certara?

Summary

How does National Research compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

National Research (NRC) Competitors

NRC vs. SDGR, TDOC, GDRX, CERT, and HSTM

How does National Research compare to Schrodinger?

Do insiders and institutionals believe in NRC or SDGR?

Is NRC or SDGR more profitable?

Do analysts rate NRC or SDGR?

Which has more volatility & risk, NRC or SDGR?

Does the media refer more to NRC or SDGR?

Which has stronger valuation & earnings, NRC or SDGR?

Summary

How does National Research compare to Teladoc Health?

Do insiders & institutionals believe in NRC or TDOC?

Does the media favor NRC or TDOC?

Which has better earnings & valuation, NRC or TDOC?

Do analysts prefer NRC or TDOC?

Which has more volatility & risk, NRC or TDOC?

Is NRC or TDOC more profitable?

Summary

How does National Research compare to GoodRx?

Do analysts prefer GDRX or NRC?

Is GDRX or NRC more profitable?

Which has better earnings and valuation, GDRX or NRC?

Which has more risk & volatility, GDRX or NRC?

Does the media prefer GDRX or NRC?

Do institutionals & insiders hold more shares of GDRX or NRC?

Summary

How does National Research compare to Certara?

Do analysts recommend NRC or CERT?

Is NRC or CERT more profitable?

Which has more volatility & risk, NRC or CERT?

Does the media favor NRC or CERT?

Do insiders and institutionals hold more shares of NRC or CERT?

Which has stronger earnings and valuation, NRC or CERT?

Summary

How does National Research compare to HealthStream?

Do analysts rate HSTM or NRC?

Is HSTM or NRC a better dividend stock?

Which has higher earnings and valuation, HSTM or NRC?

Which has more volatility and risk, HSTM or NRC?

Is HSTM or NRC more profitable?

Does the media prefer HSTM or NRC?

Do insiders & institutionals have more ownership in HSTM or NRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools